Registration, technology adoption and public production of a medicine: study of atazanavir

Authors

  • Carla Cristina de Freitas da Silveira Instituto de Medicina Social, Universidade Estadual do Rio de Janeiro (IMS/UERJ), Rio de Janeiro, RJ Author
  • Marilena Cordeiro Dias Villela Corrêa Instituto de Medicina Social, Universidade Estadual do Rio de Janeiro (IMS/UERJ), Rio de Janeiro, RJ Author
  • Wanise Borges Gouvea Barroso Instituto de Tecnologia em Fármacos, Fundação Oswaldo Cruz (Farmanguinhos/Fiocruz), Rio de Janeiro, RJ Author
  • Tatiana Aragão Figueiredo Instituto de Tecnologia em Fármacos, Fundação Oswaldo Cruz (Farmanguinhos/Fiocruz), Rio de Janeiro, RJ Author

DOI:

https://doi.org/10.22239/2317-269X.00740

Keywords:

Registration, Adoption, PDP, Atazanavir, Public Health

Abstract

Brazil was one of the first countries in the Global South to include in its public health policies robust control measures against HIV/Aids. Thus, in 2015, approximately 450,000 patients were under treatment by the Unified Health System. The sanitary registration is a crucial step for the drug entry into the domestic market, what configures a very favorable element for the drug access. Several sectors of society, even if based on different reasons, act in favor of the incorporation of new technologies; this fact, ultimately, favorably weighs in controlling the epidemic. In this work the atazanavir antiretroviral cycle is discussed through a descriptive documental study; that cycle involves: the selection of the drug by therapeutic consensus; the sanitary registration; and the definition of technological incorporation strategies for a national drug production. In 2003, the registration of atazanavir was granted in Brazil: only three months after being granted by the FDA in America and only five and a half months before being granted in Europe. This resulted in the rapid inclusion in the recommendations and in a therapeutic consensus being adopted in Brazil as the preferred drug (1st choice) in 2004. Moreover, atazanavir’s development became the object of a public-private partnership –known as Productive Development Partnership (PDP)-, inside the hegemonic policy of adopting new health technologies, defined by the Ministry of Health.

Downloads

Download data is not yet available.

Author Biographies

  • Carla Cristina de Freitas da Silveira, Instituto de Medicina Social, Universidade Estadual do Rio de Janeiro (IMS/UERJ), Rio de Janeiro, RJ

    NÚCLEO DE INOVAÇÃO TECNOLÓGICA DE FARMANGUINHOS (NIT-FAR)

    PROPRIEDADE INDUSTRIAL E INOVAÇÃO TECNOLÓGICA

  • Marilena Cordeiro Dias Villela Corrêa, Instituto de Medicina Social, Universidade Estadual do Rio de Janeiro (IMS/UERJ), Rio de Janeiro, RJ
    Instituto de Medicina Social - Departamento de Ciências Humanas e Saúde
  • Wanise Borges Gouvea Barroso, Instituto de Tecnologia em Fármacos, Fundação Oswaldo Cruz (Farmanguinhos/Fiocruz), Rio de Janeiro, RJ

    NÚCLEO DE INOVAÇÃO TECNOLÓGICA DE FARMANGUINHOS (NIT-FAR)

    PROPRIEDADE INDUSTRIAL E INOVAÇÃO TECNOLÓGICA

  • Tatiana Aragão Figueiredo, Instituto de Tecnologia em Fármacos, Fundação Oswaldo Cruz (Farmanguinhos/Fiocruz), Rio de Janeiro, RJ

    NÚCLEO DE INOVAÇÃO TECNOLÓGICA DE FARMANGUINHOS (NIT-FAR)

    PROPRIEDADE INDUSTRIAL E INOVAÇÃO TECNOLÓGICA

Published

2016-08-30

Issue

Section

Articles

How to Cite

Registration, technology adoption and public production of a medicine: study of atazanavir. (2016). Health Surveillance under Debate: Society, Science & Technology , 4(3), 18-27. https://doi.org/10.22239/2317-269X.00740

Most read articles by the same author(s)